<DOC>
	<DOCNO>NCT02880475</DOCNO>
	<brief_summary>This open-label , randomize , single-dose , parallel group study . The objective study assess pharmacokinetics oxycodone naloxone oxycodone/naloxone ( OXN ) prolong release ( PR ) tablet 5/2.5 mg ( OXN 5/2.5 ) 20/10 mg ( OXN 20/10 ) Chinese patient moderate severe chronic non-malignant pain .</brief_summary>
	<brief_title>OXN PR Tablet 5/2.5 mg and20/10 mg PK Study Chinese Moderate Severe Chronic Non-malignant Patients</brief_title>
	<detailed_description>It conduct assess pharmacokinetics OXN 5/2.5 OXN 20/10 tablet . Subjects allocate sequence two strength group accordance random allocation schedule ( RAS ) 1:1 ratio . Subjects attend screen visit within 14 day first ( OXN ) dose day ( Day 1 ) . Eligible subject check study unit day OXN dosing ( Day -2 ) . Subjects administer OXN dose next 2 morning ( Day 1 ) , follow overnight fast .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>1 . Adult Chinese patient moderate severe chronic nonmalignant pain . 2 . Male female subject age range 18 65 year ( include 18 65 ) , body weight ≥ 45kg BMI range 18 30 ( include 18 30 ) . 3 . Patients rate pain ( Pain Intensity Scale `` average pain '' last 24 hour ) ≥4 010 scale . 4 . Patients , able read , understand sign write informed consent prior study participation willing follow protocol requirement . 5 . Females childbearing potential less one year postmenopausal must negative serum pregnancy test screen visit checkin nonlactating . In addition , must willing use adequate reliable contraception throughout study . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilization , implant , injectables , combine oral contraceptive , IUDs ( intrauterine Device , hormonal ) , sexual abstinence vasectomise partner . 1 . Females pregnant ( positive βhuman chorionic gonadotrophin [ HCG ] test ) lactating . 2 . Use opioid opioid antagonistcontaining medication 30 day start study . 3 . Known sensitivity oxycodone , naloxone , related compound . 4 . Subjects clinically unstable respiratory disease , dysfunction biliary tract , thyroid disease , adrenal cortical insufficiency , prostatic hypertrophy require intervention ( medication surgical ) renal artery stenosis , medical condition , , opinion investigator subinvestigator , precludes entry study . 5 . Subject past ( within 5 year ) history malignant neoplasm include leukemia lymphoma . 6 . The electrocardiogram examination result abnormal , opinion investigator subinvestigator , clinical significance . 7 . Subjects abnormal liver function ( value exceed upper limit normal AST , ALT total bilirubin Screening Period ) abnormal renal function ( value exceed upper limit normal serum creatinine Screening Period ) . 8 . Patients contraindication study medication . 9 . Subjects psychiatric disorder participation study may , opinion investigator subinvestigator , pose unacceptable risk subject . 10 . Subjects current past ( within 5 year ) history substance alcohol abuse , subject give positive result drug abuse test Screening Period , subject , opinion investigator subinvestigator , demonstrate addictive substance abuse behavior . 11 . Subjects uncontrolled seizure convulsive disorder . 12 . Subjects receive interventional therapy ( surgery , paracentesis , etc ) arthritis study period . 13 . History current condition might interfere drug absorption , distribution , metabolism excretion . 14 . Any history frequent nausea emesis regardless aetiology . 15 . Participation clinical drug study 3 month precede initial dose study . 16 . Use medication include vitamin , herbal and/or mineral supplement course study , Vitamin D , calcium supplement continue use female contraceptive medication HRT . 17 . Consumption alcoholic beverage within 48 hour study drug administration , refusal abstain alcohol least 48 hour last study drug administration . 18 . Blood blood product donate within 90 day prior study drug administration anytime study , except require protocol . 19 . Positive result urine drug screen ( opioids , barbiturate , amphetamine , cocaine metabolite , methadone , diazepam cannabinoids ) , alcohol breath test , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( Ab ) , human immunodeficiency virus ( HIV ) test qualitative syphilis test . 20 . Patients moderate severe hypohemia ( HGB &lt; 90g/L screening ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Moderate severe chronic non-malignant pain</keyword>
</DOC>